USE OF TRANSCRIPTOME-MODIFYING AGENTS AND CHEMOTHERAPY OR RADIOTHERAPY AGAINST CANCER

摘要

The invention relates to the use of transcriptome-modifying agents in order to prevent malignant cells from undergoing the necessary genetic changes in order to combat cell insult and survive chemotherapy or radiotherapy. Said combination of transcriptome-modifying agents comprises agents that inhibit the DNA methylation machinery plus a substance that inhibits histone deacetylation. The invention relates to a treatment kit which involves the administration of an effective dose of hydralazine and valproic acid or a salt of same in the case of magnesium valproate, which is intended for use with radiotherapy or chemotherapy in the treatment of patients cancer.